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Interleukin-2 (IL-2) is a pleiotropic cytokine demonstrated to be effective in treating cancer. 
However, clinical use of IL-2 can be associated with severe side effects including gastrointestinal 
toxicity (GT). Similar GT symptoms are observed in inflammatory diseases such as Crohn’s 
Disease (CD). Interestingly mounting evidence indicates a role for IL-2 in CD, but the underlying 
mechanisms are unknown. Indeed, studies on the in-vivo activities of IL-2 have mostly focused on 
secondary lymphoid organs and immune cells associated with them. Very few studies have 
addressed how IL-2 signals impact populations of immune cells in the gut. Here, we aim to identify 
and compare the effects of systemic IL-2 administration on six major leukocyte population and 
their subsets in mice using multicolor flow cytometry. While we confirmed previously observed 
changes in specific immune cell populations in the spleen, very few changes were seen in the gut 
and gut associated lymphoid tissues. Unexpectedly, a sharp decline was seen in B cells, most 
notably in Peyer’s Patches, in mice treated with IL-2. Our data furthermore indicates that B cells 
in IL-2 treated mice undergo enhanced apoptosis in Peyer’s Patches. Some studies suggest that 
changes in B cells may contribute to development of CD. Thus, this study may aid in defining 
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CHAPTER ONE: - INTRODUCTION 
 IL-2 and IL-2 receptor system 
Since the discovery of retroviruses, scientists have attempted to grow certain ones in laboratories. 
To do so, they needed to culture T cells. In the 1970s, a team of researchers led by Robert Hallo 
cultured T cells by stimulating lymphocytes with phytohemagglutinin, a protein found in plants, 
and then searching for the production of growth factors. As a result, the team identified interleukin-
2 (IL-2). IL-2 was discovered in 1976 as a growth-promoting factor for T lymphocytes [1] and 
purified in 1980 [2]. IL-2 belongs to the γ chain family of cytokines [3]. This family also includes 
IL-4, IL-7, IL-9, IL-15, and IL-21. IL-2, an autocrine and paracrine growth factor, is secreted 
primarily by CD4 T cells also called as T helper cells (Th), but also by CD8 T cells also called as 
Cytotoxic T cells (Tc). Upon encountering an antigen, activated CD4+ T cells begin producing IL-
2, followed by the expression of the IL-2 receptor. This reaction allows the rapid and selective 
expansion of the antigen-specific effector T-cell population (CD8 and CD4). 
 
Paradoxical to IL-2 stimulating an effector response, it is responsible also for downregulating 
immune responses to prevent autoimmunity. This effect was revealed when IL-2 knockout (KO) 
mice developed an autoimmune disease with robust T-cell involvement in the place of no expected 
T-cell growth. This is now known to be caused by the failure of T regulatory cells (Tregs) to 
develop in IL-2 KO mice. Tregs downregulate the immune response and require IL-2 for their 




The IL-2 trimeric receptors consist of three chains: IL-2Rα (CD25), IL-2Rβ (CD122), and γc 
(CD132) [4]. The α chain (CD25) of the receptor does not participate in signalling, but is, instead, 
responsible for increasing the binding affinity by 10 to 100-fold. In addition to being in Tregs, this 
receptor is only found on activated CD8 and CD4. 
 
The expression of CD25 is tightly regulated. T-cell receptor stimulation and IL-2 binding lead to 
the expression of CD25; thus, IL-2 acts as a positive feedback loop, leading to the production of 
more IL-2 and the sustained expression of high-affinity IL-2 receptors. However, IL-2 can also 
bind in the absence of CD25, except a greater number of receptors are expressed. The binding 
affinity of these receptors to IL-2 are less than the high affinity receptors. thus, the receptor is 
termed an intermediate affinity-binding receptor. Although intermediate affinity binding receptors 
are mostly present on memory CD8 T cells and on natural killer (NK) cells, these receptors can 
also be found on naïve CD8 and memory CD4 T cells in low levels. After receptor binding has 
occurred, the newly produced IL-2 receptor is internalized and its components degraded, but CD25 
is recycled back to the surface. CD122 and γc cause signal transduction through pathways such as 
JAK-STAT (Janus Kinases Signal Transducer and Activator of Transcription Proteins) , 
phosphoinositide 3-kinase (PI3-K), and the mitogen-activated protein kinase pathway (MAPK), 
resulting in greater production of IL-2. These pathways impact gene expression to regulate cellular 




In addition, IL-2 functions as a paracrine growth factor for NK cells and enhances NK cytotoxic 
activity by binding to an intermediate affinity receptor. Overall, IL-2 stimulates the proliferation 
and differentiation of CD4 and CD8 cells and is produced chiefly by these cells. However, IL-2 is 
also produced in a minimal amount by NK cells, B cells, and Dendritic cells (DC’s) in at least 
some situations [5]. 
 IL-2 immunotherapy 
Following the discovery of IL-2 in 1976, a use for it was sought in therapeutics. Its potent ability 
to stimulate Tc and NK cells, which are involved in responses against tumors, meant that high-
dose IL-2 immunotherapy trials began in late 1980s. In 1986, a 33-year-old woman was the first 
person to be entirely healed by aggressive IL-2 therapy. In that trial, 25 patients with metastatic 
cancer were treated: 4 out of 7 patients with metastatic melanoma and 3 of 3 patients with 
metastatic renal cancer exhibited regression of cancer [6]. Many trials followed this breakthrough, 
as reviewed in [7], and the success rate achieved was between 10 and 20%. Thus, in 1998, IL-2 
was approved by the U.S. Food & Drug Administration for the treatment of metastatic melanoma 
and in 1992 for renal cell carcinoma.  
 
Many issues are associated with the effects of the therapy. Capillary leak syndrome, hypotension, 
neural symptoms, substantial weight gain, increased serum creatinine and bilirubin levels and 
gastrointestinal symptoms all posed many problems. Furthermore, gastrointestinal symptoms, 
including severe diarrhea, nausea, and vomiting, were reported in the majority of the patients. 
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Occasional cases of bowel haemorrhage, stomatitis, infarction, perforation, acute pancreatitis, and 
gastrointestinal bleeding occurred. Stress-induced gastric-acid secretion and the administration of 
nonsteroidal anti-inflammatory agents to control fever predispose patients receiving IL-2 to 
develop peptic ulcer disease. The use of anti-inflammatory drug impacts the immunomodulatory 
and antineoplastic effects of therapy. All these symptoms lead to early termination of the treatment, 
thus hampering the potential beneficial effects of the therapy [8-10].  
 
Surprisingly, later, low-dose IL-2 therapy was utilised to stimulate the production of Treg cells to 
improve autoimmune conditions in animals. It is firmly established that Tregs are required to 
prevent autoimmune diseases, and their depletion, whether it is hereditary or induced because of 
certain conditions lead to a variety of autoimmune diseases and inflammatory responses. Some of 
these responses include type 1 diabetes (T1D), hepatitis virus infection induced vasculitis (HCV), 
chronic graft versus host disease (GvHD), systemic lupus erythematosus (SLE), alopecia areata, 
gastritis, and colitis. Mice lacking IL-2 or lacking functional IL-2 receptor developed severe 
ulcerative colitis (UC) and produced multiple autoantibodies , although colitis developed delayed 
mild focal intestinal inflammation when mice were housed in germ free conditions [11-13]  
 
Low-dose IL-2 produced greater levels of Tregs and the treatment was well tolerated. This finding 
marked the beginning of utilising low-dose IL-2 to stimulate the production of Treg cells in 
humans to improve autoimmune and allo inflammatory conditions. Zorn et al (2006) treated 
chronic myelogenous leukaemia patients’ after hematopoietic cell transplantation with low-dose 
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IL-2. CD4+ T Regs and Foxp3 expression in CD3+ peripheral T cells were found to be increased 
many folds  Similarly, in treating T1 D, IL-2 therapy was found to be safe and dose dependent 
[14]. The same observations of an increase in Tregs was observed in other diseases. There are 
ongoing clinical trials testing the effect of low-dose IL-2. 
 
Although low-dose IL-2 therapy led to a significant drop of toxicity, there were adverse effects. 
Toxicity remained a problem and clinical trials were discontinued due to intolerable side effects. 
According to Yang et al [15], the common reasons for this cessation were hypotension and patient 
refusal. In the trial for low-dose IL-2 therapy for chronic GvHD, bacterial infection caused the 
deaths of three patients. Therefore, further clinical trials in this area are required to resolve these 
problems. 
IL-2/anti-IL-2 monoclonal antibodies 
 
 




Many groups have tried to find ways to curb the negative effects of IL-2 treatment. IL-2C was one 
of the ways of doing this, and is still being tested on mice. Boyman et al. (2006) demonstrated that 
IL-2-neutralising monoclonal antibodies skew the balance of responding lymphocyte population 
dramatically in a mouse[16]. Paradoxically, the antibodies upregulated the function of IL-2 instead 
of downregulating it. Memory CD8 cells and NK cells, which expressed only dimeric receptors, 
proliferated. The IL-2C made with S4B6 led to a 20 to 1000-fold increase of CD8 cell in vivo. 
Another monoclonal antibody clone JES6.1, stimulated the increase in CD4+ Tregs and a low 
increase in CD8 cells but prevented the stimulation of other cells. The reason for these two very 
different results depends on the receptor: S4B6 worked by blocking the interaction between IL-2 
and CD25; whereas, JES6.1 blocked CD122 [17]. 
 
The IL-2/S4B6 IL-2C has been proven to possess significant antitumor activity in mice. In a study 
, IL-2 expression plasmid was simultaneously injected with IL-2 in a B16 melanoma model [18]. 
The study found significant tumour removal in the lungs of experimental mice. Although published 
data by Tomala et al.[19] reveal that IL-2/JES6.1 also stimulates CD8+ T cells in some of the 
tumour models, IL-2/S4B6-driven expansion is superior than the former. Two different studies 
focused on treating mice in conjugation with antibiotics and alone. Mice treated early after tumor 
inoculation or treated with antibiotics prior to treatment with anti-IL-2 displayed prolonged 
survival and, in some cases, significant improvement. As explained previously, IL-2-mediated 
toxicities are poorly understood, except vascular leak syndrome (VLS). In this context, Krieg et 
al.([20] compared the effect and toxicity of recombinant IL-2 and rIL-2 antibody complex (S4B6) 
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on VLS. They observed reduced toxicity with a greater increase of CD8+ T cells. The reason VLS 
caused toxicity was found to be CD25 expressing lung epithelial cells via increased nitric oxide 
production. 
 
With respect to IL-2/JES6.1 IL-2C, it has been majorly tested in terms of autoimmune disease and 
inducing immunosuppression, especially following organ transplantation. This testing is obviously 
because of the complex’s ability to expand Tregs, which facilitates immunosuppression and 
initiates tolerance without affecting the CD25- cells. Injecting mice with IL-2/JES6.1 prevents the 
rejection of allogeneic pancreatic islets without the use of any other immunosuppression in the 
host mice [21]. In NOD (non-obese diabetic mice), IL-2/JES6.1 has been proven to impair several 
autoimmune diseases, including T1D and myasthenia gravis [21]. In conjunction with rapamycin, 
IL-2/JES6.1 has been demonstrated to be effective in experimental autoimmune encephalitis 
(EAE). Furthermore, IL-2/JES6.1 has been found to ameliorate type 2 diabetes by increasing Tregs 
in adipose tissues [22]. 
IL-2 Relation with inflammatory bowel disease (IBD) 
IBD encompasses disorders that involve chronic inflammation of the gut. IBD primarily comprises 
two types – CD (Crohn’s Disease) and ulcerative colitis (UC) – and their symptoms usually involve 
severe diarrhoea, abdominal pain, fatigue, and weight loss. As explained above, IL-2 also causes 
severe gastrointestinal toxicities, including diarrhoea and vomiting, which are very similar to the 




A number of existing studies in the literature have examined the amount of IL-2 present in CD 
patients. It has been widely adopted in the field that a marker for immune activation is the 
expression of soluble IL-2 receptor in the serum. A study of 30 patients suffering from CD reported 
that IL-2 or IL-2R was significantly found in patients with active CD. The concentration of soluble 
IL-2 was found to be correlated with the disease activity measured by the Harvey-Bradshaw index 
[23]. Furthermore, a report by Mahida et al. of 15 patients with active CD (six ileal, five ileo-
colonic, and four colonic) demonstrated a high amount of IL-2 in the plasma [24, 25]. However, 
the levels in that study did not correlate with the disease activity index. In another study, in which 
the authors examined the intestines of 12 children with active CD, they found an abundance of 
CD25+ cells in lamina propria (LP) in CD, which the authors concluded to be T cells [26]. 
Moreover, when sIL-2R beta (CD122) was measured, in a different study, in the serum of 31 CD 
patients, a positive and significant correlation existed between sIL-2R levels of alpha and beta 
chains, but not in UC patients or in healthy controls [27]. In yet another study, of 12 children 
suffering from CD, the levels of IL-2, along with other inflammatory cytokines, wwas increased 6 
to 9-fold [28]. 
 
In addition to measuring IL-2 receptor expression, different studies have measured the levels of 
IL-2 messenger RNA (mRNA). Mullin et al. determined IL-2 mRNA levels using a quantitative 
reverse transcriptase polymerase chain reaction method. In CD, higher levels of IL-2 mRNA 
transcripts were detected in the mucosa from areas of active inflammation, but in areas that were 
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histologically normal, levels were similar to control subjects [29]. However, IL-2 mRNA levels 
were significantly (P < 0.02) increased, but only in active CD, not in UC or controls [30]. 
 
IL-2 caspase 3 chimeric protein was designed to target cells that express the high-affinity IL-2 
receptors. In experiments performed by Shteingart et al., in which they treated Dextran Sulphate 
sodium (DSS) colitis-induced mice with IL-2 caspase 3 chimeric protein for 3 to 5 days, they 
achieved up to 78% improvement in disease activity index with intravenous injections of 15 
mg/mouse/day. Furthermore, IL-2 caspase 3 decreased neutrophil and macrophage infiltration to 
the inflamed tissue by up to 57%. Moreover, the Bcl2/Bax ratio, which is elevated in both 
experimental colitis and in human CD, decreased dramatically following treatment [31]. 
 
All the above mentioned studies indicate that IL-2 can be involved in the pathogenesis of CDD 
due to its pro-inflammatory nature. 
Role of innate and adaptive immune cells in IBD 
There are many different subsets of adaptive and immune cells which may be involved in CD. 
Continuing below are various experimental evidence that IL-2 can impact them   
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CD4 T cells 
CD4 T-cell subsets and the cytokines produced by them (Th1-IFN- γ and TNF α, Th2-IL-4 and, 
Th17- IL-1 7 and Tregs) have long been recognised as being involved in IBD, as reviewed in [32-
34]. 
 
There exists a considerable body of literature focusing on the involvement of Th cells (CD4 T 
cells) in CD. CD4+ T lymphocytes, which commit to Th1 T-cell development, express a 
transcription factor called T-bet. A study has proven that T-bet-deficient T cells failed to induce 
colitis in vivo, suggesting that overexpression of T-bet is sufficient and essential to promote Th1-
mediated colitis [35]. Th1 T cells produce IFN-γ and TNF-α. Ito et al. demonstrated the 
involvement of IFN-γ by treating an IFN-γ KO mouse versus a wild-type (WT) mouse with DSS 
and comparing the effects. They. found that the IFN-γ KO mouse manifested attenuated colitis; 
whereas, the WT mouse underwent a serious complication of colitis and died thereafter [36]. In 
addition to IFN-γ, TNF-α has been proven to be involved in the inflammatory reactions in CD. 
Many mouse models of colitis have been established. One better-established model, among many, 
is the SCID (Severe combined Immunodeficiency) model, in which the transfer of syngeneic 
splenic CD4+CD45RBhigh T cells in SCID mice develops IBD. Studies have demonstrated that 
repeated treatments of SCID mice with neutralising antibodies against TNF  attenuate or even 
prevention of colitis induction [37, 38]. In yet another mice model, in which TNF α is produced 
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systemically, the authors found that the mice displayed increased mucosal and systemic TNF-α 
levels compared with WT controls (P<0.001), as well as severe chronic ileitis [39].  
 
Recently, IL-17 has been identified as an important player in IBD [40]. IL-17 is involved in the 
production of many pro-inflammatory factors, including TNF-α, IL-6, and IL-17, pointing to an 
important role of IL-17 in localizing and amplifying inflammation [41-44]. There is evidence that 
IL-17 produced by distinct lineage of CD4 T cells differentiates into inflammatory phenotype in 
the presence of IL-23 and IL-1β, produces IFN-γ, and suppresses FoxP3 expression; thus, not 
allowing cells to convert into Tregs. This plasticity of IL-17 and Treg cells may morph the 
regulatory response in IBD [45], which reveals that Th17 cells might be responsible for IBD. 
 
Tregs produce cytokines such as IL-10 and TGF-β. In IL-10-deficient mice, most animals were 
growth retarded and anaemic and suffered from chronic enterocolitis [46]. Tregs have been found 
to be suppressed in various models of IBD [47], and the transfer of Tregs has been demonstrated 
to prevent colitis in many disease models of mice, as reviewed in [48].   
 
In addition to the mouse studies, many clinical studies suggest the involvement of CD4 T cells and 
its subsets in CD. In a clinical study performed on 46 Chinese patients suffering from CD, the data 
demonstrate the increased levels of Th1 and Th17 subsets relative to the serum in the healthy 
donors. In contrast, the Th2 cells and serum IL-4 levels were similar to the controls (healthy 
donors) [49]. Additionally, another group confirmed the increased presence of circulating memory 
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(CD45RO + CD4+ T lymphocytes in peripheral blood from active CD patients. The cells lacked 
the receptor CD28 (null), which might be involved in a mark of disease activity and exhibited 
resistance to apoptosis [50]. Another viewpoint concerning the involvement of T cells in IBD 
comes from cases of patients with IBD and human immunodeficiency virus (HIV). Studies have 
revealed that, because CD4 cells are depleted in HIV patients, the remission of IBD occurs [37, 
51]. However, other, controversial data exist and suggest no such possibility [37, 52].  
 
Moreover, a different subset of Th cells expressing NKG2D – a molecule more prominently found 
in CD8+ T cells, γδ T cells, and NK cells and recognise mica (stress-induced histocompatibility 
complex) – was found in the LP in CD patients with a Th1 cytokine profile, compared with the 
controls [53-55]. Furthermore, human intraepithelial cells present in the gut endothelial lining do 
not activate T helper cells in the normal state, but activated Th cells with significant IFN- γ are 
found in IBD patients [56]. Moreover, activated Th1 cytokine IFN-γ is found significantly in IBD 
patients [36, 57] 
 
TNF-α also increased in active CD. In organ cultures of involved IBD, mucosa was proven to 
spontaneously produce increased amounts of TNF-α than normal mucosa [58]. In addition, anti-
TNF-α therapy has produced notable improvements in CD patients [59], implying that TNF-α 
might play an active role in CD. This possibility points out that Th1 cytokines contribute to 
inflammation in IBD. Thus, considering all the above cases, IBD patients display an increase in 
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CD4 T-cell activity. However, it is not yet clear if the changes in any of the T-cell subsets are the 
primary cause of disease or secondary to the inflammation response [60]. 
 
Overall, the literature pertaining to T cells, its subsets, and IBD strongly suggest the involvement 
of T cells in CD. 
CD8 T cells 
Many reports provide sets of data of either increased or decreased activity of CD8+ T cells in CD 
[61]. In 1998, a colon biopsy of a CD patient revealed the infiltration of CD3 cells with a large 
proportion of CD8 cells. This patient was treated with immune replacement therapy – intravenous 
gamma globulin (IVIG) therapy – after which her health was regained. An in-vitro study 
attempting to explain the working of this treatment performed it on in-vitro lymphocytes, revealing 
that IVIG strongly reduces T-cell proliferation by suppressing antigen-induced IL-2 [62]. A recent 
study performed gene-expression profiling of CD8+ T cells during CD and UC. The study found 
several pathways were upregulated including IL-2 signaling [63]. All these findings underscore 
that CD8+ T cells may play a pathophysiological role in the occurrence of CD in the gut. In one 
experiment, the influence of intestinal epithelial cells on the cytokine expression of CD8 and Th 
cells from patients with IBD and HC was tested. It was found that IFN-γ-producing CD8+ 
lymphocytes in patients with IBD significantly increased. In contrast, HC did not respond to the 
epithelial stimulus. Even in an inactive state of disease in IBD patients, exert an increased capacity 
for IFN-γ induction in CD8+ lymphocytes. This finding demonstrates that IFN-γ could result in the 
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worsening of IBD [64]. In another study, CD8+ IL-17 cells were found to be higher in patients 
with IBD. Double-expressing IFN-γ+ IL-17+ and Foxp3+ IL-17+ CD8+ T cells were also identified, 
indicating possible CD8+ plasticity [65]. In another experiment, the authors found that IFN-γ-
producing specific CD8+ T cells could induce acute and relapsing colitis [66]. Finally, CD8 T-cell 
subsets produce cytokine similar to CD4; thus, they are likely to play a role in IBD [67]. 
Gamma delta (γδ) T cells 
Several animal [68, 69] and human studies [70-74] have pointed out that deficiency in γδ cells 
plays an important role in IBD, but this hypothesis is controversial. One of the studies involved 
CD patients with γδ deficiency in peripheral blood [71, 74, 75]. Treatments for IBD involving 
azathioprine and anti-TNF therapy increased the number of these cells in the patients, resulting in 
the reduction of inflammation symptoms [70, 73]. Conversely, another study found decreased 
numbers of γδ T cells in the colon, but the cells were activated and unusually located in the IBD 
patients, stimulating a Th1 response [75]. Very recently, IL-17-producing γδ T (γδT-17) cells have 
proved to be an important early source of IL-17 in many inflammatory settings and are emerging 
as an important participant in protumor immune responses. There is the expression of high-affinity 
IL-2R on γδT-17 cells. However, γδT-17 cells were found to be enriched, not depleted, in IL-2-
deficient mice [76].  All these results suggest that IL-2 affects γδ T cells significantly and that γδ 




B cells serve two major functions: first, they act as ‘professional Antigen Presenting Cells’ (APCs), 
presenting the antigen on the cell surface; and second, they secrete antibodies. The B-cell role in 
CD has not been greatly explored, and whether B cells are involved in the aetiology of CD remains 
a debatable topic.  
 
In 1993, Yacyshyn et al found an increased presence of memory-cell B cells in CD patients, both 
in the gut and the serum [77]. They attributed this result as the cause of intestinal permeability (IP) 
[78]. IP is thought to be a key initiating event in CD [79, 80]. In a healthy human or mouse 
intestinal mucosa, immunoglobulin A(IgA) producing a B-cell system is prominent in the gut. IgA 
is present to provide non-inflammatory first-line defence functions – setting a state of tolerance, 
explained further in the review [81] by Brandtzaeg.  
 
IgA’s other function is to provide a barrier to pathogenic microbes and non-necessary antigens. 
The intestine becomes more permeable to these broad arrays of antigens due to disharmony among 
the immune system in the gut in IBD. Since, in the abovementioned study, the authors found an 
increased expression of B cells, they considered these cells to be responsible for disrupting the 
homeostasis. They tested this hypothesis through the inability of the intestine to exclude larger-
sized molecules (antigens – lactulose and mannitol), causing intestinal inflammation, which was 




Various changes are observed in B cells in CD, as reviewed in [81]. Local IgA production 
downregulates in CD lesions, and excessive production of IgG has been found; this excessivity of 
IgG depends on the severity of the inflammatory disease. B cells suppress the action of neutrophils; 
thus, downregulating the action of pro-inflammatory cytokines [82]. Polymeric IgA B cells also 
block the non-specific biological amplification mechanism triggered by serum-derived IgG 
antibodies [83]. In IBD lesions, the chronicity of this change may result in the failure of antigen 
elimination. This result could be why 25% of colonic CD specimens exhibit mucosal invasion in 
contrast to normal intestine specimens. Furthermore, an increased number of CD patients were 
observed with selective IgA deficiencies (B cells). This change results in less-restricted leukocyte 
extravasation into the mucosal lesions [84] and, thus, an increase in pro-inflammatory cytokines 
such as TNF-α. Since B-cell functions are dysregulated in CD patients and IBD lesions, it could 
be possible that changes in B cells are involved in the pathogenesis of CD. However, due to a lack 
of data, this idea demands further attention. 
 
Concerning IL-2, it has not been actively accepted that B cells proliferate in the presence of IL-2, 
although some research supports the notion that IL-2 is one of the growth factors for B cells, and 




MΦ, or mononuclear phagocytes, also serve as APCs. The primary role of MΦ is to ingest and kill 
microbes and ingest dead host cells. In human non-inflamed intestinal mucosa, chemokines such 
as TGF β and IL-8 [90, 91] contribute to the recruitment of monocytes, which then turn into 
residential MΦ in the small intestine. Furthermore, normal human colonic and intestinal mucosa 
lack CD14, and CD14 is upregulated in the presence of bacterial lipopolysaccharide. In contrast, 
the inflamed intestinal endothelial cell lining in CD patients displays high levels of adherence 
factors that promote the migration of blood monocytes, as proved in murine models of mice [92]. 
Thus, there is a high level of recruitment of monocytes in gastrointestinal mucosa, meaning 
increased MΦ. MΦ in inflamed (CD) intestinal mucosa exhibit respiratory burst activity, which is 
absent in normal gut mucosa [91]. In addition, MΦ in the inflamed tissue release pro-inflammatory 
cytokines such as TNF-α [93], IL-1β, IL-6, and inducible nitric oxide synthase, contrary to normal 
mucosal MΦ producing IL-10 to maintain Treg function [92]. Thus, MΦ play a significant role in 
turning normal environment to an inflammatory surrounding.  
 
Regarding the IL-2 receptor presence on MΦ, it was found that, in a tissue section of normal ileum, 
fewer IL-2 receptor MΦ were present; whereas, in inflamed mucosa, many IL-2 receptors were 
visible [94]. However, whether these receptors are functional is debatable. IL-2 has been found on 
activated monocytes, but not resting [95], and on alveolar MΦ in patients suffering from 
pulmonary sarcoidosis [96]. In another study on CD, CD25+(IL-2 receptor) cells were found in 
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abundance in the LP mononuclear cells, especially in the submucosa. This result reveals the 
presence of IL-2 receptors on MΦ and may suggest their relation in IBD. 
Dendritic cells  
DC’s are APCs, and are primarily of two types: classical DC’s relocate themselves to lymph nodes 
for antigen presentation and respond to microbes; whereas, plasmacytoid DCs respond early to 
viral infections by providing type 1 interferons. DC’s respond differently to different types of 
microbes, which signals the nature of the microbes [97, 98]. In the murine gut, DC’s have the 
capability of upregulating IL-10 and IL-4 and less IFN-γ. Gut DC’s can make TGF-β also [99-
101]. Alternatively, DC’s from inflamed CD patients express CD40 more than in non-inflamed 
CD patients or healthy controls. Production of CD40 causes IL-12 production, supporting Th1 
cytokine production and TNF-α [97]. In the murine model of colitis, colonic LP DC’s exhibit 
evidence of activation [102]. DC’s either help in the activation of colitogenic T cells or aid Tregs 
in their suppressive function regarding IBD [103, 104]. 
 
Production of IL-2 by DCs has been demonstrated to impart crucial functions in both innate and 
adaptive leukocytes. Current research suggests that microbes are the most effective stimuli to 
trigger IL-2 production in DC’s by activating the calcineurin/NFAT signalling pathway Moreover, 
it was found that deleting IL-2 in CD11c(high) MHCII (high) cells results in colitis that resembles 




Neutrophils, or polymorphonuclear leukocytes, are phagocytic cells that activate MΦ for their 
removal; their sustained existence leads to excess inflammation [106]. Neutrophils have been 
consistently associated with IBD. It has been established that leucocyte migration is significantly 
lower in CD, and that (mainly) neutrophils reduced the level of chemotaxis at the inflammatory 
sites [90, 107, 108]. It has been postulated that this limited infiltration of neutrophils can be 
attributed to the circulating inhibitors of chemotaxis or the altered MΦ in CD [109]. Furthermore, 
this defect in recruitment causes the incomplete clearance of microbes, inducing a strong 
secondary immune response and, thus, increased susceptibility to bacterial infections [110].  
 
All the above mentioned defects and the even less expression of the Fc receptor have been 
associated with IL-2 therapy also, explaining the increased susceptibility to infections. Recent 
studies have proven that human neutrophils express both the β and γ chains of the IL-2 receptor, 
but have not found any trace of the IL-2Rα receptor. Furthermore, it has been indicated that IL-2 
prevents the apoptosis of human neutrophils [111, 112]. Human PMNs also become activated by 
IL-2 after binding through the IL-2R beta present on the cell surface [113, 114]. NK and PMN 
cells play a central role in IL-2-induced VLS [115]. This finding indicates that IL-2 may indirectly 




NK cells and CD8 cells share similarities regarding development, lytic mechanism, morphology, 
and cell-surface phenotype [116]. Both types of cell express receptors that are recognised by MHC 
class I glycoprotein. Concerning receptors, NK cells have, generally, two types – activating 
receptors (e.g. for NKG2D) and inhibitory receptors (e.g. for NKG2A) [117]. Furthermore, these 
cells express the IL-2/15Rb-chain (CD122) and the common g-chain (CD132) that are used as 
receptor components for multiple cytokines and are sufficient to stimulate proliferation in response 
to high concentrations of IL-2 [118, 119]. It has been demonstrated that human NK cells can be 
successfully expanded from PBMC fractions of peripheral blood in the presence of IL-2 [120], and 
that expanded cells are highly toxic. Thus, NK cells recognise and kill foreign antigens and secrete 
several cytokines such as IFN- γ, playing an immunoregulatory role. 
 
According to old research, these cells tend to decrease in CD [121, 122], but recent research 
suggests that CD16+ NK cells increase in the colonic LP of IBD patients [123]. In addition, 
NKp44(+)/NKp46(+) NK cells are disrupted in the intestinal mucosa of patients [124]. Furthermore, 
there are mixed reports concerning whether mRNA levels of IL-2 are increased or reduced in 
inflamed mucosa of active CD [125-127]. A recent paper describes NK cells as saving mice from 
DSS-induced colitis by regulating the neutrophil function by using its NKG2A receptor. There 
have been many advancements regarding the NKG2D receptor as well. A recent phase II clinical 
trial revealed that an antibody against NKG2D induced clinical remission of CD in some patients, 
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suggesting that NKG2D and its ligands are of importance in the pathogenesis of CD [128]. This 
receptor has been found on inflamed intestinal cells [128-130]; thus, it somehow contributes to the 
pathogenesis of IBD.   
Gastrointestinal immune system (GIS) 
 
Figure 2:- Immune cells in the GALT (gut associated lymphoid tissue) 
The GIS is a complex and sophisticated structure that not only saves the organism from pathogenic 
insults, but also makes it hospitable for all the gut commensal organisms (microbiota) that reside 
in the body. The GIS plays a pivotal role in maintaining the host relationship with food antigens 
and sustaining permeability for nutrient absorption. 
 
The GIS consists of four major lymphoid areas:Peyer’s patches (PPs), mesenteric lymph nodes 
(MLNs), LP, and intraepithelial lymphocytes (IELs). This system harbours the most complex 
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populations of immune cells in the body, and various subsets of populations change during the 
steady state and the state of inflammation. 
 
The gastrointestinal system has many layers of different tissues specialised in different functions. 
A basement membrane is a thin membranous layer of connective tissue in the intestinal villi that 
separates a layer of epithelial cells from the underlying LP. The IEL’s are located above the 
basement membrane, lying between the columnar epithelial cells. PPs are considered secondary 
lymphoid tissues that are embedded on the gut wall of the small intestine. PPs resemble lymph 
nodes in shape and there are 7 to 10 in the small intestine of each mouse. The MLNs are present 
in the mesentery and are usually 1 to 4 in number. All these organs are separated from each 
other, but the immune populations in them form a complex, interconnected network that 
responds differently in the steady state and the infected state. Therefore, these lymphocyte 
populations should be analysed when studying the immunological status of the intestine, for 
example, in oral immunisation or in intestinal disease (including infectious diseases and tumours). 
As there are different immune compartments, every compartment inhabit different compositions 
of cells and perform different functions. 
Lamina propria (LP) 
LP comprises mostly MΦ (132), CD4+ T cells (128), and relatively fewer DC’s [131-133], as well 
as containing CD8+ T cells (128), FoxP3+ regulated T cells, B cells – mostly IgA-producing B 
cells [134, 135], eosinophils, and some neutrophils [136-138]. Typical antibody markers can be 
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used to help search for T cells, B cells, etc. in gut LP, but there is a great debate among the scientific 
community concerning the characterisation of gut MΦ and DC’s.  
 
Both types of cell arise from a common precursor in bone marrow and belong to a mononuclear 
phagocyte system (MSP) network [139]. MΦ are tissue-resident cells and do not move farther than 
their tissue destination [140]. The common classical marker used for describing MΦ is CD11b+. 
Above, MΦ were identified as the largest population in the gut than the other organs using marker 
F4/80 [141, 142]. F4/80+, intermediate MHCII+, and CD11b+ MΦ are known to be found in close 
contact with the epithelium of the gut [142].   
 
DCs when reside sessile in the cells, display an immature phenotype (i.e. low expression of 
MHCII) and high endocytic activity. However, as DC’s are stimulated, MHCII expression 
increases and costimulatory molecules expression is upregulated. Classical DC’s are then called 
MHCII+ CD11c+ DC’s.  
 
However, over the years, this classification has been challenged with more markers, such as 
CX3CR1+, and by the fact that CD11c and CD11b are used interchangeably for populations 
expressing these markers, depending on the immunological state of the surroundings. CX3CR1+ 
cells were previously called DC’s, but more recently are used for MΦ. CD103+ CD11b+ CD11c+ 




Altogether, there are studies that refer to CD11b+ CD11c- as MΦ, and CD11b- CD11c+ as DC’s 
[144, 145]. Therefore, we, in this project, follow the classical classification of DCs and MΦ. 
Peyer’s patches (PPs) 
PPs exhibit about 60-70% of B cells (B220+) [146]. B cells further comprise various subsets – 36-
40% naïve B cells, and approximately 20% activated cells. Among the activated B cells, 
approximately 10-12% are IgA+ B cells. Furthermore, PPs contain 25% T cells (CD3+), 10% DC’s 
(CD11c+), and less than 5% MΦ (F4/80+) or polymorphonuclear neutrophil (Ly-6G+). Among the 
T cells, almost half are CD4+ T cells [147]. Among the CD4+ T cells, 85% are memory T cells 
(CD25−CD45RBlo), 10% are naïve (CD25−CD45RBhi) and 5% are regulatory T cells 
(CD25+CD45RBlo) [148].  
 
Distinct subsets of DC’s, based on their cell-surface marker expression, together with their 
location, have been identified in PPs [149, 150]. All the subsets express CD11c and major 
histocompatibility complex class II antigens but differ regarding their expression of CD8α 
(lymphoid) and CD11b (myeloid) molecules. Lymphoid CD11c+ CD8α +CD11b− DC’s are 
preferentially localised within the extrafollicular T-cell-rich area of the PPs. Myeloid CD11c+ 
CD8α− CD11b+ DC’s are present exclusively in the subepithelial dome region. Finally, the ‘double 
negative’ CD8α −CD11b− DC’s are found in the Sub epithelial dome, the interfollicular region, 
and within the Follicular associated epithelium[149]. For more information on DCs in the PPs, the 
reader is referred to reviews by Jung et al [146] and Schenk et al [151]. 
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Mesenteric Lymph Nodes (MLN) 
MLN are small, bean shaped structures lying along channels of the lymphatic system in the body. 
The major contributor to the lymphocytes presents in mesenteric lymph comes from the GALT, 
specially Peyer’s Patches. A study published in 1995 by Rothkotter HJ et al [152], demonstrated 
that the output of lymphocytes in mesenteric lymph draining regions with Peyer patches is higher 
than that of lymphocytes draining areas without Peyer patches. In the study they cannulated the 
intestinal lymph duct in eight minipigs and collected the lymph, after removing the MLN, so that 
all the lymphocytes from GALT, including Peyer’s Patches can be obtained. Also, the number of 
T cells were more than the B cells [153]. Mesenteric lymph contains lymphocytes as well as 
nonlymphoid cells such as DC’s and MΦ. The lymphocytes consist of mainly CD8+ and CD4+, 
activated B cells and unstimulated lymphocytes. Almost 80% of the cells are T cells, with CD4+ 
T helper cells (about 39.5%) outnumbering the CD8+ T cytotoxic/suppressor cells (about 30.2%). 
IgM cells (about 9.2%) also outnumbered IgA cells (about 1.2%)[154]. Not many DC’s are found 
in MLN, but a specific subset of DC’s are responsible for transporting apoptotic intestinal 
epithelial cells to T cell areas of MLN.[155] 
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CHAPTER TWO: - MATERIALS AND METHODS 
Mice 
Populations of various cell types from different organs were obtained from female wild type 
C57BL/6J(B6.PL-Thy1a/CyJ) mice. These mice carry the T lymphocyte specific Thy1a (Thy1.1, 
CD90.1) and Thy.1b (Thy1.2, CD90.2) allele. These alleles are pan T cell markers expressed on T 
cells. In addition to B6 Thy1.1/Thy1.2, syngeneic B6 CD45.1 (B6.SJL-Ptprca Pepcb, Pepboy) 
female mice were also used. Allele CD45.1 is a leukocyte marker. All mice were in the range of 
6-9 weeks of age and were originally obtained from Jackson Laboratories (Stock No: - 000664, 
002014). They were then bred at the University of Central Florida Vivarium at Lake Nona. All 
experimental animal procedures were conducted in accordance with the University of Central 
Florida’s Animal Care and Use Committee guidelines. 
Cytokine complexes 
Experiments were performed by injecting IL-2 complexes (IL-2C) intraperitoneally (i.p.) in 200 
μL of PBS over a three-day period at the same time every day. Along with the treatment mice, 
control mice were injected with the same amount (200 μL) of PBS alone. Mice received 2 μg of 
recombinant IL-2 (eBioscience) premixed with 20 μg of anti-mouse IL-2 monoclonal (m) Abclone 
S4B6-1 (S4B6) (BD Pharmingen) per day. Complexes were incubated at room temperature for 20 
minutes (min.) before intraperitoneal (i.p.) injection. 
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Preparation of mice systemic organs and Intestinal Lamina Propria 
 
Figure 3:- ˜ 0.5 cm of cut pieces of small intestine 
On Day 4 mice were sacrificed and organs were harvested sequentially. Using forceps and scissor, 
incision was made on the abdominal side of the mouse cutting away the skin and then the 
peritoneum. First the spleen is removed. Then to identify the colon it is traced to its distal end and 
is cut where it joins the anus, followed by a cut 1 cm away where the intestine joins the stomach. 
The intestine along with the associated fat is then transferred to a petri dish filled with chilled 
Dulbecco’s phosphate buffered saline (DPBS) for further dissection. Continuing, peripheral lymph 
nodes and lungs are taken out as fast as possible It should be noted that further dissection of the 
intestine should be resumed immediately after the removal of all the organs from the mouse, 
otherwise recovery of cells is not well obtained. All the organs are then kept in 4mls of wash buffer 
(RPMI -500 ml, 1M Hepes - 4 ml, FBS -5 ml, PSG -10 ml) until mashed on ice.  
Finally, MLN (2-3 in number) are excised carefully from the mesentery (mesh like structure), 
composed of fat and blood vessels, followed by removal of Peyer’s patches from  
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the intestine in a dark room. Peyer’s Patches look like a dome, lying along the epithelial lining of 
the small intestine. Since they are not visible clearly against the natural background of the small 
intestine, they can be very easily seen in a dark room in minimal light, under a lamp (Picture A). 
Once they are visible the area is cut with the scissors. In general, 6-9 PP’s are obtained from a B6 
mouse. All the organs are then mashed using a rubberized end of a 3 ml plunger in a 100 μm 
stainless steel screen cell strainer standard test sieve utilizing 10 ml wash media, then transferred 
into a 15 ml falcon tube using a transfer pipette. The falcon tubes are then centrifuged and 
resuspended in wash media, counted using haemocytometer and stained as required. However, 
with the lung, the resuspended solution is filtered through a 70 μm filter in a 50 ml conical flask, 
followed by a rinse of 10 ml media of the original tube and filtering again, so that cells are not left 
behind in the original tube and in the filter as well. The media with the cells is then centrifuged, 
resuspended in the required media and cells are counted. 
 




 Simultaneously, the intestine is flushed with ice cold DPBS, cut longitudinally and washed 
thoroughly to remove lumen contents. This whole procedure should be done on ice to maximize 
cell viability. It was then cut into ~0.5-cm pieces (Picture B) and processed according to methods 
specified by Lamina Propria Dissociation kit with some modifications (Miltenyi biotec). It 
involves two major steps - in the first step, the intraepithelial lymphocytes (IELs) are disrupted 
from the mucosa by shaking the tissue in a pre-digestion solution (1× Hank’s Balanced salt solution 
containing 5 mM EDTA, 5% fetal bovine serum (FBS), 1 mM DTT, 10 mM HEPES) twice at 
37°C (15 mins). The lamina propria tissue is further treated enzymatically using the digestion 
solution (1× HBSS with Ca2+ and Mg2+ containing 10 mM HEPES) and enzymes provided in the 
kit.  
 
It is then mechanically dissociated into a single-cell suspension by using the gentleMACS™ Octo 
Dissociator with Heaters by running the gentleMACS Program m_intestine_01. Single cell 
suspension is then centrifuged and resuspended in T cell buffer ((RPMI -500 ml, 1M Hepes - 4 ml, 
FBS -35 ml, PSG -10 ml, 250μl Mercaptoethanol), counted using hemocytometer and stained as 
required. 
There were some modifications done in the protocol and reagent preparations specified by Lamina 




In the pre-digestion solutions, 4.2mM sodium bicarbonate was also added. Once sodium 
bicarbonate is added the pH of the solution maintained should be 7.4. 1M stock of sodium 
carbonate was kept at room temperature and can be used for 2 months.  
 FBS was not added in the digestion media as serum has been shown to inhibit collagenase. 
 EDTA was always made a day prior to the treatment and the PH of the EDTA was 
maintained to be between 7.4-8.  
 DTT is known to be very unstable compound. It should be always stored at -20ºC once it 
is reconstituted in water. For that reasons, fresh aliquots of DTT were made and stored at 
-20ºC freezer. DTT cannot be used after six months from the date of suspension.  
 The buffer stock of HEPES was stored at room temperature always. Therefore, the required 
solutions were made fresh during the day of the experiment.  
 Predigestion and digestion solution were kept at 37 ºC to acclimatize to the temperature 
before adding the tissue. 
 Instead of keeping the solutions for 20 mins in pre-digestion solution and 30 minutes in the 
digestion solution, the solution was kept for 15 mins and 25 mins respectively. 




Once the cells were obtained, they should be immediately stained with the required antibodies. 
The more the time is taken to stain, the more the chances are that cell will loose their viability and 
markers can get cleaved off. 
Flow cytometry 
Cytokine and surface staining were performed as previously described [157]. Briefly, cell 
suspensions were washed, resuspended in FACS buffer (PBS plus 0.5% BSA and 0.02% sodium 
azide), a cocktail of Fc block, antibodies suspended in FACS buffer is added ( For 1 sample- 1 μl 
of Fc block + required diluted antibody+ FACS buffer = 100 μl) and then incubated-on ice(2-8°C) 
for 30 minutes with minimal exposure to light. The samples were treated with anti-FcR (2.4G2, 
BioXcell) because Fc receptors are found on monocytes, MΦ, DC’s and B cells They bind 
antibodies via their constant Fc domain rather than the antigen specific Fab domain. This type 
of binding can lead to false positives and meaningless data. In order to prevent this type of 
binding, Fc blocking reagents are used which, when added to a staining protocol, can help 
minimize non-specific binding. 
 
Also saturating concentrations of the fluorochrome-labeled antibodies were added for surface 
staining to look for the desired cells. After the incubation cells are washed again with 1 ml of 
FACS buffer and resuspended in 100 μL of FACS buffer and 100 μL of FACS fix  
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Ki67- Nuclear (Proliferation) Staining. 
Ki67 is a cell proliferation marker.as it is expressed actively throughout all the stages of cell cycle. 
The staining is done according to eBioscience™ Foxp3 Transcription Factor Staining 
Buffer Set (Catalog number: - 00-5523-00). Proliferation of B cells and CD8 T cells were 
determined and the surface stains used are listed in Table (1). This protocol involves use of 
Permeabilization Buffer as it is necessary to permeabilize the cell with detergent or alcohol to 
allow antibodies against intracellular antigens access to stain intracellularly. After surface staining 
cells with the required markers, the cells are treated with 1X working solution of permeabilization 
buffer, incubated for 45 minutes, followed by washing twice and then stained with Ki67 for 30 
minutes. After the incubation cells are washed twice with 1X permeabilization buffer and 
resuspended in Facs buffer. The samples were then run on the same day. All FACS analyses was 
performed using a FACS Canto flow cytometer (BD Biosciences) and FlowJo (Tree Star) analysis 
software. 
Annexin V- 7AAD Staining 
Cell death was measured by flow cytometry using Annexin V Apoptosis Detection Kit with 7-
AAD as per manufacturer’s instructions (FITC Annexin V Apoptosis Detection Kit with 7-AAD, 





Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds 
to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the 
intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane 
asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can 
then be used to specifically target and identify apoptotic cells.  
 To help distinguish between the necrotic and apoptotic cells 7-amino-actinomycin D (7-AAD) 
solution is used. Early apoptotic cells will exclude 7-AAD, while late stage apoptotic cells will 
stain positively, due to the passage of these dyes into the nucleus where they bind to DNA. 
7-AAD (7-amino-actinomycin D) has a high DNA binding constant and is efficiently excluded by 
intact cells.  
 
The protocol starts with surface staining with the respective antibodies. The cells are washed twice 
with cold 1X Macs Buffer, and then resuspend cells in 100 µl Annexin V Binding Buffer. Then 5 
µl of FITC Annexin V antibody is added, followed by 5 µl of 7-AAD Viability Staining Solution. 
The tube is then vortexed gently and incubate for 10 min at room temperature (25°C) in the dark. 
Then 200 µl of Annexin V Binding Buffer is added to each tube. The samples were then run on 
the same day immediately after the last step. All FACS analyses was performed using a FACS 




All statistics were analyzed by GraphPad Prism. Unpaired two-tailed student t test was utilized to 
determine the significance by which two normally distributed groups differed. A P value of <0.05 
was deemed significant. All error bars represent the standard deviation. In all figures, significance 










Surface, Transcription factor 
and Nuclear stain 
Antibodies 
used 
Flurophore Clone Company 
1. T cells Anti- CD90.2+ Pacific Blue 53-2.1 eBioscience 
CD4  Anti- CD4 PE GR 1.5 eBioscience 
CD8 Anti- CD8 PERCP 53-6.7 BD-
Pharmigen 
γδ Anti- γδ APC GL3 Biolegend 
 Anti-CD44 FIT-C IM7 eBioscience 
Anti-CD45.2 FIT-C 104(RUO) BD 
Biosciences 
2. Antigen Presenting cells Anti-MHC II Pacific Blue M5/114.15.2 eBioscience 
  Anti-MHC II PERCP M5/114.15.2 Biolegend 
Anti-CD11C FITC N418 eBioscience 
  Anti-CD11B APC M1/70 eBioscience 
3. B cells Anti-B220 PERCP RA3-682 eBioscience 
Anti-CD19 PERCP 1D3 Biolegend 
 Mature B cells Anti-IGM FIT-C RMM-1 Biolegend 
Anti-IGD Pacific Blue 11-26c.2a Biolegend 
 IgA+ B cells Anti-IGA FIT-C C10-3 BD 
Biosciences 
4. NK cells Anti-CD3 Pacific Blue 71A2 eBioscience 
Anti-NK1.1 PE 553165 BD 
Pharmigen 
5. Neutrophils Anti-CD11B APC M1/70 eBioscience 
Anti-Gr-1 FIT-C RB6-8C5 BD 
Biosciences 
6. IL-2 receptor Anti-CD25 PE 7D4 BD 
Biosciences 




7. Cell Death Staining Annexin V FIT-C NA Biolegend 
  7 AAD PERCP NA Biolegend 
8. Ki67 staining Anti-Ki67 PE SolA15 eBioscience 
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CHAPTER 3: - SIGNIFICANCE AND INNOVATION 
Immunotherapy with IL-2 was the first immunotherapy approved by the FDA (Food and Drug 
Administration) to treat cancer. Although the therapy was successful in 15-20% of the patients 
undergoing the treatments, clinical trials, often had to be stopped during the course of the 
procedure. The reasons, detailed in section (1.1) are the manifestation of severe toxicities in most 
organ systems, one of which are gastrointestinal toxicities. Currently, through literature, it is 
evident how IL-2 affects the immunology of the systemic organs such as spleen and lymph nodes, 
i.e., by changing the expression of the immune cell populations (CD8 T cells and NK cells). There 
are many clinical and mouse studies demonstrating the effect of IL-2 delivery on the said organs. 
In comparison to the systemic organs, a few groups have addressed the issue of IL-2 effect on 
lungs (vascular leak syndrome), which is one of the mucosal organs. However, in the studies, they 
explained the impact of IL-2 on endothelial cells, which also possess IL-2 receptor, but little is still 
known about the changes in numbers of immune cells. Contrary to systemic organs and the lungs, 
not many studies describe what effect IL-2 causes in the immune cell populations in the gut and 
how it results in such drastic toxicities.  
  
The gut encompasses the largest population of immune cells. It is the organ which deals with the 
commensal bacteria and creates an environment of tolerance to let the needed commensal organism 
survive without causing an immune response against them. But it also must be able to respond to 
potentially harmful pathogens and toxins. Thus, the local immune environment in the gut is 
significantly different from the systemic immune system in terms of both its inductive and 
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effective sites and the composition of various immune cell populations such as intra-epithelial 
lymphocytes, different subsets of APC’s, etc. Chronic Inflammation in the gut is sometimes a sign 
of IBD. Causes for IBD are thought to be genetic, environmental, dietary and infection caused due 
to Mycobacterium avium subspecies Paratuberculosis [158] .Despite significant research in the 
field, the etiology of IBD is not clear. Some clinical trials show the presence of the substantial 
amount of IL-2 present in Crohn’s patients not only inactive CD patients but also during inactive 
disease states. The similarity of symptoms shown by a CD patient and similar gastrointestinal 
issues observed during the therapy demands to look if IL-2 is somewhere involved in the etiology 
of CD.  
  
The first aim of this project in its broader scope will characterize the effect of IL-2 
immunologically on the cells present in the GALT - Peyer’s Patches (PP), MLN (MLN, Lamina 
Propria (LP) and Intraepithelial lymphocytes (IEL’s) of the intestine. The effects will be observed 
in an immunologically unaltered state. This contribution is significant since it may establish 
specific unknown changes of the immune cell’s populations of the GALT, caused by IL-2, which 
might not be present in the spleen. We hypothesize that such changes can be responsible for 
disrupting the homeostasis of the gut immune system. This, in turn, could contribute to effects 
observed during the IL-2 therapy in the setting of cancer and the pathogenesis of some of the 
causes of CD. We also want to bring attention to the point that the observations might be helpful 




The second aim of this project is to determine whether IL-2 will similarly or differentially impact 
immune cell subsets at distinct mucosal sites. We chose the lungs because it is the prototypical and  
vital mucosal organ. Although both the gut and lungs are mucosal organs, they are distinct in many 
ways from each other. A significant difference is the - commensal microorganisms at each site. As 
the source of antigens is distinct, it could be that these antigens might be perceived differently 
through different TLR’s or other mechanisms by the cells of these organs. This difference can 
generate a very different environment in both these organs. Thus, this aim seeks to determine 
whether IL-2 might differentially regulate immune cell subsets at various mucosal sites.  
  
IL-2 has been combined with other therapies like chemotherapy to bring down the toxic effects in 
cancer patients. Despite significant advances, clinical trial data demonstrate remission rates at best 
15-30%. Thus, there remains a need to find a safer way to use IL-2 in therapeutics potentially. The 
clinical significance of our study will be to shed light on various considerations that should be 
taken into account while using IL-2 in therapeutics. The consideration will be related to the point 
that the regulation of IL-2 is not similar to different organs. While IL-2 can be effective in treating 
melanoma but can also disrupt the immune system at a different organ-like gut. Therefore, 
researchers may need to think in terms of the organ they are targeting IL-2 with, regarding therapy.  
  
One easy way to test the effect of IL-2 on gut cells would be to perform experiments in a petri 
dish. However, in-vitro experiments introduce to two problems. First, the differential way IL-2 
reacts in a petri dish versus the way IL-2 will respond in-vivo. As mentioned, and explained, IL-2 
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is a pleiotropic cytokine. Certain conditions and presence of cells determine its reaction to a 
particular stimulus. Second, it is impossible to create the gut- microbiome environment in a petri 
dish. The amalgamation of different kinds of food antigen, microbiota, complex immune networks 
could change the way a cytokine will response in a petri dish vs. the in-vivo model. 
  
Therefore, we chose to perform experiments in a steady-state (immunologically unaltered state, 
“not ill”) mouse, by treating the mouse with IL-2C treatment and look at the effects in the gut 













We hypothesize that acute treatment with IL-2C elicits differential quantitative changes 


























Figure 5:- IL-2C selectively increases CD8+ T cell and NK cell population in spleen and 
lymph nodes in vivo. 
Naïve C57BL/6 Thy1.1/1.2 mice received 2 μg per day of recombinant IL-2 premixed with 20 μg 
of anti-mouse IL-2 monoclonal (m) Ab- S4B6-1 for three days. On the fourth day, cells were 
harvested and analyzed (A) C57BL/6 mice injected with PBS serving as control. (B)  C57BL/6 
















Figure 6:- IL-2C selectively increases CD8+ T cell and NK cell population in spleen and 
lymph nodes in vivo. 
(A) Gating strategy to segregate NK cells using CD3 and NK 1.1. (B) Gating strategy to segregate 























Figure 7:- IL-2C selectively increases CD8+ T cell and NK cell population in spleen and 
lymph nodes in vivo.  
(A) Increase in absolute cell numbers of splenocytes and immune cell populations in the lymph 
nodes after IL-2C treatment. Effect of IL-2 treatment on total cell numbers and frequency of (B) 
Spleen T cells (5 fold) (C) LN T cells (2 fold) (D) Spleen - NK cells (4 fold) (E) LN – NK cells (2 
fold) (Summary of at least 4 - 9 experiments with at 2 mice per group). All error bars represent the 
standard deviation and significant differences determined with unpaired, two-tailed, students t-





Result 1: - IL-2C treatment cause increased expansion of CD8+ T cells and NK cells in 
systemic lymphoid organs – Spleen and Lymph Nodes. 
S4B6 IL-2 Complex  
To study the effects of IL-2 treatment on the total number of immune cells of the systemic 
lymphoid organs, we treated non-infected (steady state) mice intraperitoneally with 2 μg per day 
of recombinant IL-2 (eBioscience) premixed with 20 μg of anti-mouse IL-2 monoclonal (m) 
Abclone S4B6-1 (S4B6) (BD Pharmingen) to form IL-2 complexes (S4B6). 
 
IL-2 complex (S4B6) exhibited potent biological activity and imparts target cell specificity which 
made its use widespread among the scientific community in mouse models. Number of reasons 
such as increased half-life and lower toxicity can be attributed to increased biological activity of 
this complex.  
 
Our procedure involves injecting IL-2C complex for three days as this dose has been employed 
and proven effective as by many labs as one of the optimal physiological doses to obtain a IL-2 
response [5, 159]. The dose is not toxic enough that it would cause death, but it can promote a lot 
of inflammation [159] 
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Panel and Gating Strategy 
To look for the effect of the complex on immune cells i.e. (CD8+ T cells and NK cells) we needed 
a panel and a gating strategy. The panel as shown in table 1 comprises 5 antibodies in 5 different 
colors to explore the presence of T cells subsets, whereas panel 2 utilizes only 2 antibodies to look 
for NK cells. 
 
In addition to CD8+ T cells there are other subsets of T cells – CD4+ T cells and Gamma delta (γδ) 
T cells. The complex is known to not cause a major expansion of CD4+ T cells. The said 
populations of T cells - CD4+ T cells and γδ+ T cells have been shown to be involved in CD as 
explained in the introduction [49, 76, 160, 161] . Apart from being involved in the mentioned 
disease, γδ T cells have been also been shown to get affected by IL-2 [76]. For these reasons we 
also investigated these subsets of T cells.  
 
We first optimized a 5 colour panel (Table 1) to detect distinct T cell subsets. After gating on the 
live cells based on FSC- SSC lymphocyte gate, the next step was double cell exclusion analysis.  A 
doublet is a single event that consists of 2 or more independent particles. The particles are bonded 
while they pass through the laser in the FACS machine, such that the instrument is incapable of 
distinguishing them as individual events. As shown in the figure 6 (A) doublets need to be 
identified and excluded, so that cells can be further analyzed and to avoid artifacts to make staining 
clearer. To analyze the doublets, we are required to select a channel to compare area, height, and 
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width. We attained this by choosing FSC-A and FSC-H. The only requirement for this channel is 
that it should be scaled linearly. This strategy is used throughout this study  
 
Further on, we distinguished all leukocytes using the marker CD45-2 or CD45-1 depending on the 
mouse genotype and then gate the T cells using pan T cell marker CD90-2, found on all T cells 
originating from the thymus. We then mark  
distinct subsets of T cells i.e γδ, CD4 and CD8, distinguished according to the surface molecules 
they express. So, using the antibody for γδ we first gated on γδ positive cells, revealing a separate 
population of γδ negative cells, then through further gating on γδ negative cells we isolate CD4 
and CD8 T cells separately. The gating strategy is shown in fig 6 (B). The graphs are then plotted 
on Prism comparing the frequency and total cell numbers obtained after the gating. The gating 
strategy required to gate NK cells is shown in fig 6 (A). 
Effects on T cells and NK cells 
Earlier research has shown that IL-2 complexes cause expansion in the number of memory CD8 T 
cells and NK cells from 10-100 fold in the spleen and the lymph nodes [16]. Our results confirm 
the significant in-vivo expansion of these immune cells in the same organs. The absolute numbers 
of CD8+ T cells and NK cells remained significantly higher than at the baseline after treatment in 
both spleen and lymph nodes (Fig 7 A). The frequency increased by 20% and total cell numbers 
of CD8 T cells quadrupled (Fig 7 B, C). The total cell numbers doubled for NK cells with a 10% 
increase in the frequency (Fig 7 D, E). Hence, the expansion was driven by enhanced in-vivo 
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proliferation of CD8 T cells and NK cells. We found a significant 2-fold total cell increase of 
Gamma delta (γδ) T cells in spleen but no significant changes in CD4 T cells. (Fig 7 B, C). 
 
Each dot in the graphs (Fig 7 A) represent the absolute immune cells population of that organ in 
an individual mouse with or without treatment on a given day. Thus, the graph is a cumulation of 
data sets collected over a span of experiments with different mice. Over the duration of these 
experiments, the results show the counts to be relatively similar and present a repetitive pattern 
each time, clearly indicating the expansion of CD8 T cells and NK cells in systemic lymphoid 
tissues. These results are reproducible providing relevant information which can be statistically 
analyzed.  
  
Therefore, having validated our experiments data against known impacts of IL-2C treatment in 
secondary lymphoid organs (i.e. the increase in CD8+ T cells and NK cells) we went on to test the 





















Figure 8:- IL-2C treatment cause non- significant quantitative changes in CD8+ T cells and 
NK cells in the gut tissues (GALT). 
(A) Decrease in absolute immune cell populations in PP’s and increase observed in MLN after IL-
2C treatment. No significant effect of IL-2 treatment on total cell numbers and frequency of (B) 
PP’s T cells (C)M LN T cells (D) PP’s - NK cells (E) 2-fold increase of total NK cells numbers is 
observed in MLN. (Summary of 5-10 experiments with 2 mice per group). All error bars represent 
the standard deviation and significant differences determined with unpaired, two-tailed, students t-























Figure 9:- IL-2C treatment cause non- significant quantitative changes in CD8+ T cells and 
NK cells in the gut tissues (GALT). 
(A) Increase in absolute immune cell populations in LP and IEC after IL-2C treatment. 2-3-fold 
increase can be observed in (B) LP T cells (C) IEC T cells (D) LP - NK cells. The graphs are from 
only one experiment with a mouse per group. The graphs only give a hint towards the increase 
number of cells, but not infer any of the changes. More experiments are needed to observe a 




Result 2: - IL-2C treatment cause non- significant quantitative changes in CD8+ T cells and 
NK cells in the gut tissues (GALT).  
We next tested the effects of IL-2C on the GALT (PP’s, MLN, IEC, LP). We hypothesize that 
changes will be observed in the gut tissues that are not observed in the spleen and vice versa. We 
base our prediction on different inductive and effective sites of gut than the spleen (systemic organ) 
where different cytokine environment and populations of immune cells exist [162]. Hence, we 
checked the effect on total numbers of immune cells focusing on CD8 T cells and NK cells in the 
gut tissues, as changes in these first populations induce by IL-2 in systemic organs in the literature 
are well described. In accordance with our first hypothesis, gut tissues showed disparate changes 
at different sites. To begin with, no significant changes were observed in absolute cell numbers in 
MLN (Fig 8A). But surprisingly, a decrease is observed in total cell number of Peyer’s Patches 
(Fig 8A). With regards to the CD8 T cells, both Peyer’s Patches and MLN exhibited no significant 
differences as shown in (Fig 8B and (Fig 8C) respectively. However, with respect to NK cells, 
MLN displayed significant difference of 5-fold after the treatment (Fig 8E). No significant 
difference was observed in total cell numbers of NK cells in PP’s (Fig 8D). Overall the results 
concur that decrease in PP’s is not due to dropping down of CD8 T cells and NK cells numbers, 
and thus warranted further testing of other cell types. 
 
The other two gut organs LP and IEC showed 2 to 3-fold changes in total cell numbers of CD8+ T 
cells (Fig 9B, 9C). But the results mentioned are representative of only one experiment. This is 
because of extended amount of time it took to optimize LP and IEC dissociation protocol to isolate 
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these cells. Therefore, from now on LP and IEC will be discussed in relation to one experiment 
just to shed light on potentially expected results. More experiments are needed to understand if the 
changes are significant or not.  
 
Taken together the data suggest no significant changes in total number of CD8 T cells in gut organs 
in comparison with the spleen. Therefore, based on these findings, the plausible next step was to 
examine other major cell types, especially in Peyer’s Patches, to find out the cause for reduction 
in absolute cell numbers. For this reason, we  looked for B cells and other APC’s as B cells 






















Figure 10:- IL-2C Treatment differentially affects frequency and total cell population of B 
cell numbers in Peyer’s Patches. 
Heat map depicting effect of IL-2 treatment on total cell numbers and frequency of all immune 
cell population as mentioned in the map. The heat map is only representative of three experiments 
with 2 mice. per experimental day, with a total of 3 mice per condition. Standard deviation and 
significant differences determined with unpaired, two-tailed, students t-tests (α = 0.05, and * P< 



















Figure 11:- IL-2C treatment differentially affects frequency and total cell population of B 
cell numbers in Peyer’s Patches. 
(A) Gating strategy to segregate B cells and Antigen Presenting cells using CD45-2, MHCII, B220, 










Figure 12:- IL-2C treatment differentially affects frequency and total cell population of B 
cell numbers in Peyer’s Patches. 
No significant effect of IL-2 treatment on total cell numbers and frequency of (A) B cells in the 
Spleen or (B) LN In contrast to spleen and lymph nodes 2-fold decrease of B cells observed in the 
C) PP’s. Decrease in B cell numbers can define the decrease in absolute cell numbers in PP’s. (E) 
No significant increase of B cells is observed in MLN. (Summary of 5-10 experiments with 2 mice 
per group). All error bars represent the standard deviation and significant differences determined 
with unpaired, two-tailed, students t-tests (α = 0.05, and * P< 0.05, ** P< 0.005, *** P< 0.001, 
**** P< 0.0001). NS represents non- significant. Another gut organ – Lamina Propria also show 
an increase in total number of B cells and frequency by 2-3-fold. But the graphs are from only one 
experiment with a mouse per group. The graphs only give a hint towards the increase number of 
cells, but not infer any of the changes. More experiments are needed to observe a significant 







Figure 13:- IL-2C treatment do not cause significant change in frequency and total cell 
population of MΦ and DC’s in any of the organs  
No significant effect of IL-2 treatment observed on total cell numbers and frequency of DC’s and 
MΦ of (A) Spleen – minimal increase observed in MΦ in the spleen but not in DC’s (B) LN C) 
PP’s (D) MLN (Summary of 5-10 experiments with 2 mice per group). All error bars represent the 
standard deviation and significant differences determined with unpaired, two-tailed, students t-






















Figure 14:- IL-2C treatment do not seem to cause significant change in frequency and total 
cell population of MΦ and DC’s in any of the organs  
No significant effect of IL-2 treatment on total cell numbers and frequency of (A) Lamina Propria 
– minimal change observed in MΦ in the Lamina Propria(B) IEC’s. But the graphs are from only 
one experiment with a mouse per group. The graphs only give a hint towards the increase number 
of cells, but not infer any of the changes. More experiments are needed to observe a significant 









Figure 15:- IL-2C treatment affects total cell population of neutrophils in spleen and MLN, 
but not any of the other gut organs. 
Significant effect of IL-2 treatment observed on total cell numbers but not frequency of (A) Spleen 
(D) MLN T cells. In contrast to spleen no other gut organ except MLN showed any significant 
difference All error bars represent the standard deviation and significant differences determined 
with unpaired, two-tailed, students t-tests (α = 0.05, and * P< 0.05, ** P< 0.005, *** P< 0.001, 
**** P< 0.0001). NS represents non- significant. Another gut organ – Lamina Propria also show 
an increase in total number of neutrophils. But the graphs are from only one experiment with a 
mouse per group. The graphs only give a hint towards the increase number of cells, but not infer 







Result 3: - IL-2C treatment differentially affects frequency and total cell population of B 
cell numbers in PP’s  
In order to address the decrease in cell population in PP’s further examination was conducted on 
changes in another cell population in PP’s. Research indicates that PP’s consists of approximately 
60-70 % B cells and 10-15 % Antigen presenting cells (APC’s) [146]. Additionally, MΦ and DC’s 
are shown to be involved in CD, making it important to also explore the effect of IL-2 complex on 
these cells [94, 104, 163, 164]. We also looked for neutrophils – innate immune cells as they are 
found to be involved in CD [109, 115]. In summation, we further probed populations of B cells, 
APC’s and neutrophils through flow cytometry in all the organs in order to determine how IL-2 
signals impact their frequency and numbers (Fig 10).  
 
The gating strategy employed in this experiment in order to dissect the B cells is illustrated in (Fig 
11A). The first step involved in gating is using FSC- SSC to gate dead cells out along with doublet 
exclusion analysis, as described before (Fig 10A). Further to this, cells are distinguished using 
MHC class II antibody- as it is present on most of the B cells and professional APC’s. We will 
differentiate B cells using the pan- B cell marker - B220. Further, drawing from the fact that APC’s 
are MHCII+ but B220- , we will continue to differentiate the subset of this cell population utilizing 
two conventional markers for MΦ and DC’s – CD11b and CD11c, respectively. In this study, we 
limit our analysis of APC subsets to the MHCII+ B220- CD11c+ CD11b- subset called as DC’s and 
MHCII+ B220- CD11b+ CD11c- subsets as MΦ Other combinations ,such as MHCII+ B220- 
CD11b+ CD11c+ - are also seen, but because of  scientific disagreement over classification of 
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markers for DC’s and MΦ in the gut, we have not analyzed APC further. Considering this dilemma, 
we chose to follow the conventional strategy as described above [145].  
Effect of IL-2C on B Cells  
We found that the frequency of B cells in PP’s decreased by 30% and total cell population went 
down by 2-fold (Fig 12C). Thus, it is clear that the decrease in absolute numbers of cells in PP’s 
is due in large part to a significant decrease in B cells. B cells were also investigated in other 
organs. Spleen and Lymph node demonstrated no significant change (Fig 12A, 12B). In 
comparison with the other organs of the gut except PP’s, no change in B cells frequency or total 
cell number was observed in any of the other organs. Thus, change in B cells is exclusive to PP’s. 
This represent a novel and exciting finding that supports our hypothesis of different actions of IL-
2 administrations at different sites.  
 
Based on one experiment B cells in Lamina Propria seems to be increasing by 4-fold (Fig 12E). 
This observation is again in contrast with the effect observed on spleen B cells after the treatment.  
Effect of IL-2C on Antigen Presenting cells  
 The IL-2C treatment did not result in quantitative changes in DC’s or MΦ in any organs except 
the spleen (in MΦ). A slight increase in total cell numbers was observed in the MHCII+ B220- 
CD11b+ CD11c+ cells in the spleen, lymph nodes (Fig 13A, 13B). Parallelly, a slight increase was 
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also observed in PP’s and also the MLN too (Fig 13C, 13D). However, LP demonstrated increase 
in macrophage number by 2-fold (Fig 14A). Since this is an observation from just one experiment, 
we cannot establish a concrete difference in the expression of these cells before and after the 
treatment. 
Effect of IL-2C on Neutrophils  
Neutrophils are separated from other leukocytes using the phenotypic markers Gr-1and CD11b. In 
mouse models, MDSCs (myeloid-derived suppressor cells) are found myeloid cells expressing high 
levels of CD11b (a classical myeloid lineage marker) and Gr-1 (granulocytic marker). High 
expression of these markers is used to distinguish neutrophils. CD11b(high), Gr-(high) and MHCII 
(-ve) cells are called as neutrophils in the gating strategy (Fig 11B). Robust and significant increase 
of total cell numbers and frequency was found in neutrophils in spleen (Fig 14A) Among the gut 
organs only MLN (Fig 15D) and LP (Fig 15E) only one experiment) showed increase in 
neutrophils. PP’s did not show any difference either in the frequency nor in the total cell numbers. 
(Fig 15C). 
 
Taken together, Antigen presenting B cells showed complete contrast in the total cell numbers and 
frequency before and after the S4B6 IL-2C treatment. There is no significant difference between 
the number of DC’s or MΦ, but these cell types need further division based on more different 
markers mentioned in the literature.  Hence, effect of IL-2C may be similar in some cases 
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between spleen and gut organs, but mostly administration of IL-2C have differential effects 




















Figure 16:- IL-2C treatment do not cause increase in mean of FSC of CD8 T cells but cause 
increase in B cells in PP’s. 
Effect of IL-2 treatment on the mean of FSC of CD8 T cells, NK cells and B cells in (A) Spleen 
CD8 T cells ( 4 times increase) (B) Spleen NK cells (3 times increase) (C) Spleen B cells – No 
significant increase (D) PP’s CD8 T cells – No change in the size (E) PP’s NK cells – Minimal 
increase in the size (F) PP’s B cells – increased expansion of the mean of FSC the treatment The 
increase size can either be due to expansion of the size of the cells or proliferation.(Summary of at 
least 4-9 experiments with 1 mice per group). All error bars represent the standard deviation and 
significant differences determined with unpaired, two-tailed, students t-tests (α = 0.05, and * P< 
0.05, ** P< 0.005, *** P< 0.001, **** P< 0.0001 
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Figure 17:- IL-2C treatment cause death of B cells in PP’s.  
Effect of IL-2 treatment on proliferation of CD8 T cells and B cells measured by ki-67 staining in 
(A) Spleen- 2 times increase in proliferation of CD8 T cells but no change observed in B cells 
(B)PP’s - 4 times increase in proliferation in CD8 T cells but no change in B cells. (C) Gating 
strategy to stain for live and dead cells using 7 AAD and annexin V staining. Measurement of dead 
B cells by performing 7AAD and annexin V staining in (D) Spleen. The percentage of dead cells 
are either same or less in treated mice which means that IL-2 is not causing any death of B cells 
after treatment in spleen (E) PP’s: 2 times increased death of B cells after the treatment. (Summary 




Result 4: - IL-2C treatment cause death of B cells in PP’s. 
To further probe the finding that B cells are decreasing in total cell numbers in PP’s we looked if 
cell size of B cells changes after IL-2C treatment. One easier way to confirm any alteration in the 
cell size is through comparing forward side scatter of the cells. Increase in size of cells of the 
forward side scatter of is suggestive of a possible activity of cell division or their activation. 
 
We found that in the control organ spleen, expansion of CD8 T and NK cell size is observed (Fig 
16A, 16B). This phenomenon is suggestive of the fact that they are either dividing or activating. 
These results also corroborate with the results in existing literature, thereby confirming the division 
of aforementioned cells after IL-2 treatment. Apart from CD8 T cells and NK cells, no alteration 
in the size of B cells is observed in spleen (Fig 16C). 
 
In contrast to spleen, no significant difference was observed in the cell size of the CD8+ T cells in 
PP’s (Fig 16D). Although the size of B cells was noticed to have slightly increased, suggestive of 
either activation or proliferation (Fig 16F). Further analysis was needed to ascertain if this slight 
change was caused by cell expansion. So, we employed a strategy of staining the cells with staining 
marker - Ki67, a nuclear protein expressed in dividing cells. The results demonstrated 3 times 
proliferation of CD8+ T cells in spleen ((Fig 17A) 33.5 % to 96.9 %). CD8+ T cells in PP’s also 
proliferated in the presence of IL-2 complex. But no significant change in size was observed in B 
cell (Fig 17B). The percentage increase in spleen B cells is from 50.7 to 56.5 (Fig 17A), whereas 
in PP’s it is from 30.5 to 34.2 (Fig 17B) We found that proliferation of B cells is found neither in 
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spleen nor in Peyer’s Patches after the treatment. In summation the observations suggest that 
change in size of B cells is not caused by proliferation.  
 
Thus, as B cells are not proliferating, increasing in size and their decline in cell numbers raise the 
possibility that that B cells are getting activated and dying The validity of this assumption was 
confirmed by further analysis of apoptosis by staining for dead and dying cells using 7AAD and 
Annexin V - cell viability stains. Cells with compromised membranes will stain with 7-AAD, 
whereas live cells with intact cell membranes will remain dark. 7AAD intercalates with double-
stranded DNA, with a high affinity for GC-rich regions, whereas annexin V distinguishes apoptotic 
cells by binding with phosphatidylserine (a marker of apoptosis when it is on the outer leaflet of 
the plasma membrane). The percentage of dead B cells in PP’s were observed to increase almost 
2 times after post-treatment (Fig 17E). However, in the control spleen no similar changes were 
observed. The frequency of dead B cells is almost the same as before and after the IL-2C treatment 
in spleen (Fig 17D). The gating strategy employed to look for dead cells is shown in (Fig 17C) 
 
Significant death of B cells in PP’s, but not in the spleen, after the regimen of injecting IL-2 for 
three days, implies that IL-2 is killing B cells in PP’s, which contrasts with the established activity 













Figure 18:- IL-2C cause targeted killing of naïve B cells in Peyer’s Patches  
Gating strategy to segregate naïve and effector B cells using IgM, IgD, CD21, CD93 and B220 
antibody. Effect of IL-2C treatment on subtypes of B cells in (B) Spleen – Both naïve and effector 
B cells are not affected (B) Lymph Node – No significant difference in any of the subtypes after 
the treatment. (C) Peyer’s Patches- the naïve subtypes of B cells – IgD+ and IgM+ IgD+ are 
affected and are decreasing in number and frequency. Also, the effector cell population IgM- IgD- 
do not show any significant difference. (D) MLN – IgD+ population is showing a minimal increase 
after the treatment. (Summary of at least 3-4 experiments with a mouse per group). All error bars 
represent the standard deviation and significant differences determined with unpaired, two-tailed, 
students t-tests (α = 0.05, and * P< 0.05, ** P< 0.005, *** P< 0.001, **** P< 0.0001). 
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Result 5: - IL-2C cause targeted killing of naïve B cells in Peyer’s Patches. 
We next stained for naïve and mature subsets of B cells to see if specific cohort of B cells are 
dying in PP’s after the IL-2C treatment. The gating strategy employed (Fig 14A) to look for 
different subsets involves using IgM, IgD - naïve mature B cells (IgM+ IgD+) [165], plasma cells 
(IgD -) or memory cells, CD21+ - strongly expressed on mature B cells (not clear if expressed on 
Lamina Propria B cells [166, 167], CD93- - a marker of recent B-cell generation and B220.  
 
This study has demonstrated low numbers of naive IgM+ IgD+ and IgD+ B cells in Peyer’s Patches 
(Fig 18D) after the IL-2 treatment, but no significant differences were observed in any of the IgM- 
IgD- population. In contrast to spleen, no significant difference was observed in any of the sub 
types (Fig 18B). IgM- IgD- subtype could be consisting of most of the plasma and effector memory 
cells. No significant changes in this subtype in PP’s and decrease in naïve B cells, pointed that B 
cell effectors or memory cells are not affected by IL-2C signals whereas mature naïve B cells are 










Figure 19:- IL-2C treatment might be affecting B cells indirectly.  
Effect of IL-2 treatment on CD122 receptor of (A) T cells - IL-2 CD122 expression was 
upregulated by many folds in spleen, relatively less in MLN followed by PP’s. (B) B cells- A very 
subtle upregulation of CD122 is observed in B cells. It shows that IL-2 complex does not 









Result 6: - IL-2C might be affecting B cells indirectly.  
Overall after the study, it is evident that IL-2C treatment is decreasing B cell numbers in PP’s and 
the cause of this decrease could be the apoptosis of naïve B cells. Since B cells were dying, the 
next step was to understand the cause of death of these cells. Prior studies have documented that 
expression of receptor CD122 is highly enhanced in CD8 T cells after IL-2C treatment and is a 
direct effect of IL-2 signaling [168]. Therefore, to understand if IL-2C is impacting the CD122 
receptor expression on B cells similarly as it impacts T cells, we looked for CD122 receptor 
expression on B cells and T cells in spleen and PP’s. If IL-2C is impacting CD122 receptor 
expression similarly as that in CD8+ T cells in spleen, then it could be hypothesized that IL-2 may 
have a direct effect on B cells. The gating strategy implemented during this experimentation 
involves the use of thymocyte marker CD90-2, pan B cell marker B220, CD45-2 and CD122. 
 
Our experiments were evident of increased expression of CD122 in spleen T cells by almost 7 
times (Fig 19A) following IL-2C treatment. In contrast to CD8+ T cells, no changes were observed 
in CD122 expression of B cells after the treatment (Fig 19B). This could imply that IL-2 has an 
indirect effect on B cells, which needs to be proven with further experiments. Hence all the 
differences shown between the GALT and the spleen proves that IL-2 is differentially regulated in 
















Figure 20:- IL-2C selectively increases CD8+ T cell and NK cell populations in lungs. 
A) Increase in absolute cell numbers of immune cell populations in the lungs after IL-2C treatment. 
Effect of IL-2 treatment on total cell numbers and frequency of (B) Lungs T cells (3 fold) (C) 
Lungs NK cells (2 fold) (Summary of at least 5- 9 experiments with at 2 mice per group). All error 
bars represent the standard deviation and significant differences determined with unpaired, two-
tailed, students t-tests (α = 0.05, and * P< 0.05, ** P< 0.005, *** P< 0.001, **** P< 0.0001). NS 















Figure 21:- Unlike gut organs, IL-2C treatment does not cause significant changes in B cells 
but results in expansion of Neutrophils. 
Effect of IL-2 treatment on total cell numbers and frequency of (A) Lungs B cells (No significant 
change) (F) Lungs APC’s – No significant change (C) Lungs - Neutrophils (2 fold) (D) No 
significant change in naïve and effector B cells in lungs (Summary of at least 5-9 experiments with 
a mouse per group). All error bars represent the standard deviation and significant differences 
determined with unpaired, two-tailed, students t-tests (α = 0.05, and * P< 0.05, ** P< 0.005, 



















We hypothesize that treatment with IL-2C elicits similar quantitative changes in lymphocytes in 













Result 7: - Insignificant change in B cell populations in lungs after treatment with IL-2C. 
Lungs are most-studied mucosal sites in the body. The lung encounters a myriad of potentially 
foreign, particles on a daily basis. As such, immune cells in this site, like GALT must gauge 
whether to respond or not. Therefore, to compare changes observed in different mucosal sites, we 
selected lungs versus other gut organs - PP’s, MLN, LP and IEC’s. GALT immune system 
comprises of four different immune sites working together to maintain the homeostasis of the 
immune system, whereas such different immune compartments are not marked in the immune 
system of the lungs. Therefore, lungs will be discussed with respect to each organ to paint a 
complete picture of similarities or dissimilarities between the two.  
 
We hypothesized that lungs will exhibit similar changes as the gut after the treatment, which means 
either no change in CD8+ T cell numbers or a decrease in B cells. Lungs are a complex mucosal 
site fighting several airborne antigens, much like the gut which fights several foods- borne and 
other antigens. 
Lungs comparison with PP’s 
Surprisingly, lungs behaved like spleen in terms of significant increase in absolute cell numbers 
and not like PP’s (Fig 20A). 2-fold to 4-fold increase in frequency of CD8 T cells and NK cells, 
and 5-fold increase in total cell numbers of CD8 T cells and 2-fold increase of NK cells was seen 
in lungs after IL-2C (Fig 20B, 20C) treatment. Also, there was a notable expansion in the size of 
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the above-mentioned cells verifying their proliferation after a regime of IL-2 treatment. These 
results suggest that IL-2C complex treatment causes expansion of cell numbers in the lungs like 
spleen. Additionally, total cell numbers did not change for B cells in the lungs (Fig 21A).  
Lungs comparison with MLN 
IL-2C induced changes in the lungs is in sharp contrast with MLN with respect to T cells. MLN 
showed no significant differences in total cell count neither for T cells nor for B cells. Although 
lungs behaved like MLN in relation to neutrophils (Fig 21C) and NK cells demonstrating increase 
in cell numbers. 
 
Therefore, considering all the results explained above it is clear that it is difficult to compare 
changes in lungs with respect to gut as a whole, but it can be done with respect to one GALT organ 
at a time, and more experiments will be needed to make a whole comparison. In the data described 
above two gut organs are behaving are completely opposite. 
 
Thus, it is evident that IL-2 does not behave the same way in all the mucosal immune 
compartments, especially in the gut. It behaves differently in different mucosal organs, albeit very 





CHAPTER 5: - CONCLUSIONS/DISCUSSIONS 
We show that IL-2 does not similarly affect immune cell populations at different sites in the body, 
but differentially impacts leukocytes in systemic lymphoid tissues such as spleen and lymph nodes 
versus the GALT. Furthermore, our studies identify a novel effect of systemic IL-2 administration 
in increasing acute death of B cells in PP’s, which is surprising, and interesting. Additionally, we 
showed that the dying B cells are only naïve B cells and the involvement of IL-2 in there could be 
indirect. Finally, we show that IL-2 impacts immune cells differentially at different mucosal sites 
(i.e. Lungs versus the gut). 
 
Boyman and sprent demonstrated a very large increase in the total numbers of CD8+ T cells and 
NK cells in the spleen and lymph nodes after treating mice with injections of IL-2 and IL-2 mAb 
(S4B6), with marked enlargement of these organs. They also found minimal effects on other cells, 
including CD4+ T cells and B220+ B cells. Our results clearly indicated no such expansion of CD8 
T cells and NK cells in the GALT in mice treated with IL-2 and IL-2 mAb (S4B6). Gut tissues like 
PP’s (20% of T cells), MLN (80% T cells), LP (60-70% CD4 T cells [169]) and intra epithelial 
layer (mostly CD8 T cells or γδ T cells [170]) constitutes T cells in fairly good frequency.  It was 
surprising to see that instead of having a predominance of T cells in these organs, the impact on 
gut by the IL-2 treatment is very different as observed in spleen and lymph nodes. No significant 
change was observed in PP’s and MLN. Additionally, in contrast to T cells, we found that the 
treatment impacted B cells in Peyer’s Patches. 
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PP’s involved in the pathogenesis of CD’s: -We found that the number of B cells decline in PP 
after an IL-2C treatment. This finding instigates a question of this mechanism’s relevance to CD 
which prompted us to investigate relevant literature. Previous studies have indicated the 
importance of PP’s in CD because they are abundantly present in the terminal ileum, an area 
predisposed to CD [171]. In 1960 and 1996, two separate groups reported that the earliest 
microscopic changes in CD were ulceration of lymphoid follicles and PP’s in the terminal ileum 
[172, 173]. Further endoscopic observations of the PP’s in a CD patients [174, 175] showed altered 
irregular surface which harbors microgranulomas and lymphoid hyperplasia when compared to 
controls. Similar observations were also noticed in patients suffering from UC [176]. As PP’s are 
an important site to sample luminal antigens, their disruption can cause an increase in the intestinal 
permeability to unwanted luminal antigens. If such a state persisted for a long time, it can disrupt 
the intestinal layer and grant entry to unwanted organism causing inflammation. Taken together, 
these results suggest that PP’s are an important organ and the alterations in PP’s in CD demands 
further investigation. 
 
Deletion of B cells could cause IBD like symptoms:- Moreover, Peyer’s Patches consists of 70-
80% of B cells [146] and through this study we found that these some of these cells die after IL-
2C treatment. Different biological therapies in various disease settings produce unwanted adverse 
effects to treatments. In view of this is one such therapy using Rituximab, a B lymphocyte 
depleting agent. Rituximab is widely used in the initial treatment of CD20-positive hematologic 
malignancies and various autoimmune disorders. It was reported to exacerbate UC in a patient 
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with refractory disease [177] . A case of a 45-year-old patient was reported in 2008, who developed 
an UC after undergoing treatment with this antibody and was not predisposed to IBD or received 
any other therapy before this [178]. Recently, a patient developed 2 episodes of fulminant colitis 
after 2 infusions with Rituximab for the treatment of disseminated B-cell marginal lymphoma 
[179]. The studies above suggest that the decline in B cells may foster the development of colitis 
in patients undergoing the therapy, although, the causation of acute severe colitis after rituximab 
therapy is not known. Considering this, more work is needed to understand the mechanism of how 
reduction in B cells can foster an environment that might lead to colitis, if at all B cells are at fault.  
 
Mice studies showing involvement of B cells in IBD: - In addition to the clinical cases mentioned 
above, some in-vivo murine studies have attempted to describe the role of B cells in colitis. 
Mizoguchi et al have found severe colitis in a double mutant mice that lack TCR-α−/− ( lack T 
cell receptor) × immunoglobulin (Ig) μ−/− (lack B cells) [180]. The findings of their study suggest 
that B cells are not required for the initiation of colitis but can suppress colitis through mucosal 
clearance of apoptotic cells. Further research by Mizoguchi et al. show that B cell subset 
suppresses the progression of intestinal inflammation by producing interleukin-10 [181], a 
cytokine which maintains immune equilibrium and prevents the development of autoimmune 
disease [182, 183]. Patricia et al [184]  showed alterations in the cytokine environment (i.e 
diminished up-regulation of IL-4, IL-10, and TGF-β ) in the gut of a B cell deficient mice (μMT) 
when compared to a wild-type mice after treatment with low doses of antigen given orally. These 
cytokines are associated with the induction of cytokine-mediated active suppression. Along with 
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this, increased Ag was also detected in the lymph of the μMT mice. The paper does not unravel 
the actual mechanisms underlying these observations. Additionally, Wang and Chu [185]  confirm 
that B cells present in the gut are implicated in the resolution of colitis, using a sulfate sodium 
(DSS)-induced colitis model. More severe disease developed in the absence of B cells, and that 
the adoptive transfer of total WT B cells to B cells-deficient mice attenuated the disease while the 
mechanisms induced are unclear. It has also been suggested that the transfer of IL-10(-/-) B cells 
attenuated colitis, indicating that B cells inhibit colitis through an interleukin-10 (IL-10)-
independent pathway. Moreover, they found CD4+ T cells to be the major contributor to the IL-10 
pool in the gut. Furthermore, Wang and Chu also showed that antibody depletion of Tregs resulted 
in an exacerbated colitis B cells- deficient model mice [186]. Interestingly, it has been found that 
B cells induce proliferation of Tregs which in turn promotes B-cell differentiation into IgA-
producing plasma cells. These results demonstrate that B cells and Tregs interact and may 
cooperate to prevent excessive immune responses which can ultimately lead to colitis. 
 
In view of the above observations and our observation of IL-2 induced B cell apoptosis we 
hypothesized that the decrease in B cells after an IL-2C treatment could be responsible for 
generating an inflammatory environment in the PP’s. Such an environment created (as a result of 
an IL-2C treatment) in the PP’s may be more susceptible to infections as the equilibrium of 
tolerance can get disturbed. This could result either in increased intestinal permeability in the gut, 
causing more antigens to cross the epithelial barrier, and/or due to the unavailability or low luminal 
IgA which is normally produced by B cells. IgA is a major immunoglobulin produced in the GALT 
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and is responsible for generating a immune response against the harmful microbiota residing in 
the gut. Thus, disruption of equilibrium in susceptible individuals caused due to deletion of B cells 
may result in severe colitis. 
 
Treating mice with IL-2 at different time points: - Currently we have treated the mice with IL-
2C for three days and assessed changes in immune cell subsets on the fourth day (i.e 1 day after 
3rd day treatment). And this time we have undertaken the task of understanding the change in 
immune cell subsets in various regions of the GALT. However, changes observed after three days 
of injection, are like a snapshot in time. We do not understand what occurs prior and after the third 
day timepoint.  Therefore, we feel it is important to perform many experiments that are possible 
in context of exploring the effect of IL-2 at different time-points including day 1 or 2 or post day 
4. This will help us in understanding if, the changes that we see after IL-2 treatment are acute or 
chronic. The observations from the suggested future study will throw light whether one day 
treatment of IL-2 is enough to observe the acute changes or the difference obtained in the immune 
cell population is chronic and persist for a long time.  
 
If the changes observed are chronic it can be hypothesized that deficiency of B cells in the PP’s 
can be of real consequence to CD’s. It can also be hypothesized that IL-2 can be involved in the 
pathogenesis of CD because of its potential ability to kill B cells and expose the gut to several 
unwanted pathogens. If changes in PP’s continue to remain the same even after dis-continued 
exposure of IL-2C, then the skewed environment that is letting loads of antigens to cross the barrier 
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through PP’s persist for an elongated interval and can ultimately result in IBD. In the gut, exposure 
to low amount of particular antigen is not harmful. But regular exposure can initiate a surmountable 
response of inflammation homing the gut. There this state of continuous inflammation can be one 
of the in the etiology in some cases of IBD.  
 
Additionally, the disruption of the intestine layer can be caused due to altered production of IgA+ 
B cells, result in shifting of the equilibrium towards the unwanted pathogens. Thus, this could 
cause alteration in the microbiome of the gut in a healthy individual. Through our experiments we 
show that there is increase in absolute numbers of CD8+ T cells and NK cells. Combined this 
increase of CD8+ T cells with decrease in B cells can alter the environment in number of ways. 
Selective transport of polymeric IgA across epithelial cells lining the mucosal surface is an 
important phenomenon to keep the commensal organisms in check. If this property of B cells is 
altered, followed by increase in CD8+ T cells effector cell populations, then the regulatory 
mechanism that control the local immune response to luminal antigens will get disturbed. Thus, 
alterations in this way can jeopardize the equilibrium of the whole gut immune system and will 
not spare the vital structures of the intestine from immune mediated destruction. 
 
Increased secretion of IL-2 can create a skewed environment: - Our observations suggest that 
naïve B cells are dying in Peyer’s Patches after IL-2C treatment. We also attempted to find out if 
death of B cells was a direct effect or an indirect effect due to IL-2 signals (CD122). CD122 gets 
upregulated after interacting with IL-2, which is clearly seen with CD8 T cells. But no such 
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upregulation of CD122 signal was observed in B cells. This supports that it can be an indirect 
effect of IL-2. There could be many reasons for the indirect effect observed. IL-2 triggers other 
cells populations, i.e. CD8 T cells and NK cells to expand and secrete cytokines that create pro - 
inflammatory condition, which can result in killing of B cells. This assumption has prompted a 
thought that, increased secretion of IL-2 without antigen exposure can result in a skewed 
environment, thus IL-2 being a dangerous cytokine, if not regulated optimally. Some light on this 
thought have shown by Strutt and colleagues [159]. They demonstrated that IL-2 administration 
can cause extremely potent lung inflammation involving NK cells, and that lung environment is 
particularly sensitive to IL-2-induced inflammation during viral infection. Thus, future studies can 
test the effector cytokines such as TNF, IL-1α, IL-1β, IFN-γ etc released by these cells at various 
intervals of time and can test to see if these cytokines are responsible for B cell death. 
 
IL-2 secretion can activate death receptors: - Within the immune system, FasL is mostly 
expressed by cytotoxic CD8+ T lymphocytes and NK cells that are activated in response to viral 
infection and malignancies. We can hypothesize that IL-2 signals can initiate such response from 
CD8+ T cells and NK cells and thus can kill B cells by activating the death receptors on them. 
Also, B cells death receptors can get activated after interacting with helper T cells. In addition to 
the extrinsic ligands, apoptotic signals can also be initiated through the intrinsic factors associated 
with Bcl-2 protein family, mitochondrial permeability and apoptosome formation. Therefore, 
studies can look for the molecules involved in the extrinsic pathway [187] on B cells and intrinsic 




Subsets of APC’s present in gut and involved in CD’s: -. In addition to the B cells, we also 
looked for APCs. We use the traditional surface markers to phenotype classical DC’s (CD11b- 
CD11c+) and MΦ (CD11b+ CD11c-). However, in the gut combination of other phenotypic 
markers are used to classify APC’s that have been interchangeably used to define DC’s and MΦ, 
such as F4/80, CX3CR1 CD103, CD14 and CD64 etc. For broader understanding, the reader is 
referred to the suggested reviews [188, 189]. Therefore, classification of these cells requires a 
multiparameter approach, which was beyond the scope of this study. 
 
MΦ and DC’s have been known to later markedly in IBD environment in the gut. In humans IBD 
has been marked with accumulation of CD14(high)CD11c(high) MΦ, rather than CD14(low) MΦ 
during the homeostatic state. Anti TNF treatment have also been shown to be accompanied by loss 
of these CD14(high) cells [190, 191]. In different mice models of inflammation, intermediates 
levels of CX3CR1 MΦ, and a unique subset of CD169+ CX3CR1+ have been mentioned in the 
cases of IBD [192, 193]. As per platt et al [194] MΦ in steady state condition are F4/80+TLR- 
CCR2- CX3CR1(high) and do not produce TNF-alpha in response to stimulation. But during 
experimental colitis, TLR2+ CCR2+ CX3CR1(int) Ly6C(high) Gr-1+, TNF-α-producing 
macrophage are present. They also showed that there is preferential CCR2-dependent recruitment 
of the proinflammatory population during colitis. CCR2 knockout mice show reduced 





Therefore, future studies can investigate these subsets and many others as various subsets have 
been mentioned to play an inflammatory role in cases of CD (colitis) in humans as well as mice, 
and their role are only starting to be understood. It could be a possibility that these subsets are 
affected by IL-2 treatment  
 
Cross Talks between APC’s: - APC’s seem to be specific to local environment in the gut. DC, 
MΦ and B-cells exhibit cross-talks among themselves for supporting critical roles. Although each 
type of APC exhibits unique functions allowing them to participate in gut immunity, with their 
official functions of activating T-cell responses by showing an antigen, APC can also interact with 
one another to directly shape immune responses. Therefore, the disturbance in the interconnections 
between these cells could result in disequilibrium, promoting a chronic state of inflammation, 
detrimental in CD or IBD. Therefore, these specific subsets need to be looked in detail to 
understand if by any way, IL-2 is causing a change in any specific markers on the cells. It can 
cause cascade of changes in all the attached mechanisms causing destruction of tolerance. 
 
Causes of CD like MAP could result in flare-ups of IL-2: - CD is considered to be a chronic 
inflammatory bowel disease. Many explanations have been proceeded to explain the cause for this 
disease however, its causation remains unclear. Genetic causes, environment changes, high fat diet 
[195] and exposure to an mycobacterium- MAP are various proposed possibilities [158]. It can be 
a possibility that the flare up and inducement in IL-2 can be based upon the above-mentioned 
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rationale, that these reasons can be the initiating triggers of release of IL-2. Therefore, the next 
step would be to test this into a diseased model where all these factors can be tested to see if they 
are actually resulting in flare ups. There is an entire possibility that increase in IL-2 due to these 
causes could create a disruption in B cells.  
 
Effect of IL-2 on lungs: - Our second aim of the project was to compare the effects of IL-2C at 
distinct mucosal sites, and we chose lungs as the representative mucosal organ. The results clearly 
showed that the effect of IL-2C was different in lungs as compared in the gut, even though both 
are mucosal sites. It is unclear what underlies these results. Some possibilities are mentioned 
below. 
 
Firstly, the difference could be because of the different cytokine mediated environment of the gut 
and the lungs [196-198]. The source of antigens found in the lungs are quite dissimilar as to the 
source of antigens present in the gut. Airborne antigens are found in the lung, whereas gut gets the 
continuous influx of food antigens and the commensal microorganisms. Thus, there are different 
kinds of signals generated and initiation of different pathways through the interaction of these 
antigens with different Toll like receptors and pattern associated molecular patterns. These signals 
can sensitize the IL-2 signals differently at both the mucosal sites. Therefore, difference in the 
mucosal environments can be one of the reasons for the difference observed in both the mucosal 
sites. Second, as mentioned above different types of APC’s are present at these two different sites. 
Differential APC subsets might respond differently to these antigens leading to differential 
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susceptibility to apoptosis after IL-2 treatment in both the organs. Third, it has been established 
that the vascular leak syndrome caused due to IL-2 treatment in the lungs is because of the presence 
of IL-2 receptors on the endothelial cells [199]. It is possible that the type and the number of IL-2 
receptors present on the endothelial lining of the gut tissues versus the lungs are different. These 
differences can cause IL-2 to react in opposite ways at both the sites, thus giving a completely 
different outcome. Therefore, studies need to be performed to tests these possibilities to understand 
which of these reasons are responsible for varied impact of IL-2 and its differential regulation at 
different organs. 
 
Summary: - The use of S4B6 IL-2C is a popular regime in studying the effects of IL-2 in various 
disease models such as cancer and many autoimmune diseases [200-203]. But the studies 
concluding the effects of IL-2 in the gut are extremely limited. These studies fail to scrutinize the 
possibility of IL-2’s adverse effects on other organs such as gut, lungs, etc. thereby, confining the 
focus upon organs such as the spleen and lymph nodes. Also, this limitation extends to the 
inclusion of looking the effects only to cell types such as CD8T cells and NK cells. However, our 
study illustrates the effects of IL-2 on B cells and it is not limited to the aforementioned cells. The 
differential effect of IL-2 on CD8 T cells, NK cells and B cells is quite clearly observed between 
the systemic lymphoid organs and Gut associated lymphoid tissue. The effect of IL-2 on these cells 
in the gut is varied than observed in the spleen. These effects could be involved in pathogenesis 
and etiology of some of the cases of CD. Therefore, there is abundant room for further research 
on the alterations caused in the immune cell subsets by IL-2 specially in the conditions of IBD. 
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The effects of IL-2C on immune cells should be understood holistically. This would bring in 
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